BUZZ-Quanterix rises on 'breakthrough device' tag for its blood test for Alzheimer’s Disease

Reuters03-05

** Shares of diagnostic company Quanterix rise 1.2% to $27.31

** Co announces that the U.S. FDA has granted its blood test 'breakthrough device' designation

** 'Breakthrough device' designation helps patients gain access to medical devices in treatments for which no approved or cleared alternatives exist

** The blood test called Simoa helps in detecting a protein, p-Tau 217, to help diagnose Alzheimer’s Disease

** The test is not intended as a stand-alone test and its results will be interpreted along with other diagnostic tools - QTRX

** Including session moves, stock has doubled in the last 12 months

(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment